# EDGAR Filing Document

**Accession Number:** 0001643918
**File Stem:** 0001214659-23-004200
**Filing Date:** 2023-3
**Character Count:** 11353
**Document Hash:** a0c58c5b459aad5711ccde8d81a27262
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-23-004200.hdr.sgml**: 20230327

**ACCESSION NUMBER**: 0001214659-23-004200

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230327

**FILED AS OF DATE**: 20230327

**DATE AS OF CHANGE**: 20230327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Midatech Pharma Plc
- **CENTRAL INDEX KEY:** 0001643918
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37652
- **FILM NUMBER:** 23761721

**BUSINESS ADDRESS:**
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **STATE:** X0
- **ZIP:** CF10 4DQ
- **BUSINESS PHONE:** 44 (0)1235 888300

**MAIL ADDRESS:**
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **STATE:** X0
- **ZIP:** CF10 4DQ

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934** 

For the month of March 2023

Commission File Number 001-37652

**<u>Midatech Pharma PLC</u>**

**(Translation of registrant's name into English)** 

**1 Caspian Point, Caspian Way, <u>Cardiff, CF10 4DQ, United Kingdom</u>**

**(Address of principal executive offices)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

 ****

This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).

**<u>SUBMITTED HEREWITH</u>**

Attached to the Registrant's Form 6-K filing for the month of March 2023, and incorporated by reference herein, is:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Press release, dated March 27, 2023 entitled<br>"New Preclinical R&D Programme Focused on Leptomeningeal Disease"  |

---

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Midatech Pharma PLC | Midatech Pharma PLC |
| Date: March 27, 2023 | By: | /s/ Stephen Stamp |
|  |  | Stephen Stamp<br> *Chief Executive Officer, Chief Financial Officer* |

---

**Exhibit Index** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Press release, dated March 27, 2023 entitled<br>"New Preclinical R&D Programme Focused on Leptomeningeal Disease"<br>|

---

## Exhibit 99.1

**Exhibit 99.1**

27 March 2023

**Midatech Pharma PLC**

("Midatech" or the "Company")

**New Preclinical R&D Programme Focused on Leptomeningeal Disease**

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.

**Background**

Many cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses<sup>1</sup>, such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy<sup>2</sup>. Oxidative Phosphorylation (OXPHOS) is another critical mechanism that enables a variety of fuel sources to be used to generate adenosine triphosphate (ATP), a molecule present in cells that provides energy for metabolic processes. When under induced stress, cancer cells switch away from aerobic glycolysis and significantly increase reliance on the alternative OXPHOS pathway. Inhibiting the OXPHOS pathway represents a potential means of targeting both primary and metastatic tumour lesions in patients. OXPHOS can be inhibited by a range of small molecule therapeutics, however systemic administration of these generally causes undesirable toxic effects in healthy cells<sup>3</sup>.

**MTD217**

Midatech's MTD217 programme explores simultaneous inhibition of key metabolic pathways, including the Warburg effect and OXPHOS. The research is centred around a number of new water-soluble drug formulations that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, disrupting metabolic functions in a highly localised manner, thus limiting off-target toxicity. The Company has already been able to demonstrate up to a six-fold synergistic effect of administering its formulation of panobinostat, known as MTX110, with an OXPHOS inhibitor *in vitro* with three patient-derived cells lines. On the back of those data, Midatech has established new patent positions to protect these combination formulations.

The Company's initial target is treatment of leptomeningeal disease, a lethal complication in which metastatic cancer cells invade the cerebrospinal fluid and central nervous system<sup>4</sup>. In collaboration with several large academic centres, Midatech is now accelerating preclinical studies to generate proof of concept data in this setting that can support a future clinical trial application.

**Dr Dmitry Zamoryakhin, MD, MBA, CSO of Midatech, commented**:

"*We are very excited about accelerating this promising programme towards first-in-human studies. It capitalises on Midatech's knowledge in direct intratumoral delivery of drugs, currently being explored in our clinical programme of MTX110 in recurrent glioblastoma. Furthermore, blockage of the OXPHOS pathway by MTD217 opens opportunities to demonstrate potential synergistic effects with checkpoint inhibitors in solid tumours as well as exploration of co-treatment with MTX110 in patients with aggressive brain tumours.*"

------

<sup>1</sup> Ahmat *et.al* Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol. 2018 Dec; 53:265-281

<sup>2</sup> Trang *et.al* Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma. Cells 2022, 11, 2956

<sup>3</sup> Emmings *et.al* Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer. *Int J Mol Sci*. 2019;20(1):229. Published 2019 Jan 8. doi:10.3390/ijms20010229

<sup>4</sup> Law *et.al* A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neuro-Oncology 24(10), 1673–1686, 202

**For more information, please contact:**

---

| |
|:---|
| <br> **Midatech Pharma PLC** |
| Dmitry Zamoryakhin, CSO |
| Tel: +44 (0)29 20480 180 |
| www.midatechpharma.com |
| **Strand Hanson Limited (Nominated Adviser and Broker)** |
| James Dance / Matthew Chandler / Rob Patrick |
| Tel: +44 (0)20 7409 3494 |
| **IFC Advisory Limited** (Financial PR and UK Investor Relations) |
| Tim Metcalfe / Graham Herring |
| Tel: +44 (0)20 3934 6630 |
| Email: midatech@investor-focus.co.uk |
| **Edison Group** (US Investor Relations) |
| Alyssa Factor |
| Tel: +1 (860) 573 9637 |
| Email: afactor@edisongroup.com<br>|

---

**Forward-Looking Statements**

Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. The Company wishes to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

Reference should be made to those documents that the Company shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange's AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, the Company does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

**About Midatech Pharma PLC**

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies, to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control
the release of therapeutics over an extended period of time (from weeks to months).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they
can be administered in liquid form directly and locally into tumours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com